RESUMEN

Currently, SARS-CoV-2 spike receptor-binding-domain (RBD)-based vaccines are considered one of the most effective weapons against COVID-19. During the first step of assessing vaccine immunogenicity, a mouse model is often used. In this paper, we tested the use of five experimental animals (mice, hamsters, rabbits, ferrets, and chickens) for RBD immunogenicity assessments. The humoral immune response was evaluated by ELISA and virus-neutralization assays. The data obtained show hamsters to be the least suitable candidates for RBD immunogenicity testing and, hence, assessing the protective efficacy of RBD-based vaccines.

Asunto(s)

Vacunas contra la COVID-19 , COVID-19 , Inmunogenicidad Vacunal , Glicoproteína de la Espiga del Coronavirus , Animales , COVID-19/prevención & control , Vacunas contra la COVID-19/inmunología , Pollos , Cricetinae , Modelos Animales de Enfermedad , Hurones , Ratones , Ratones Endogámicos BALB C , Conejos , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus/inmunología , Vacunas de Subunidad/inmunología